R. Parker

发表

Backbone and side chain dynamics of uncomplexed human adipocyte and muscle fatty acid-binding proteins.

K. Constantine, M. Friedrichs, M. Wittekind, 1998, Biochemistry.

Endoplasmic Reticulum Stress Links Dyslipidemia to Inhibition of Proteasome Activity and Glucose Transport by HIV Protease Inhibitors

R. Parker, O. Flint, R. Mulvey, 2005, Molecular Pharmacology.

Relation of vascular oxidative stress, alpha-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters.

R. Parker, M. Cap, B. Gill, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Lack of macrophage fatty-acid–binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis

Jeffrey B. Boord, R. Parker, J. Suttles, 2001, Nature Medicine.

Role of the fatty acid binding protein mal1 in obesity and insulin resistance.

R. Parker, G. Atsumi, D. Bernlohr, 2003, Diabetes.

NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein.

Stephen R. Johnson, David S. Taylor, K. Constantine, 2006, Journal of medicinal chemistry.

byinhibitingfatty-acid-bindingproteinaP2

R. Parker, G. Atsumi, M. Linton, 2007 .

Reversible modulation of the activities of both liver microsomal hydroxymethylglutaryl coenzyme A reductase and its inactivating enzyme. Evidence for regulation by phosphorylation-dephosphorylation.

R. Parker, T. Ingebritsen, H. Lee, 1978, Biochemical and biophysical research communications.

Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for LDL Lowering

R. Parker, M. Witmer, Gerald, 2014 .

Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature.

R. Parker, B. Tesfamariam, Qi Huang, 2003, Atherosclerosis.

Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors.

R. Parker, L. Hamann, M. Kirby, 2005, Bioorganic & medicinal chemistry letters.

Isolation and characterization of mevinolin resistant mutants of Saccharomyces cerevisiae.

R. Parker, M. Bard, N. Lees, 1988, Journal of general microbiology.

Phosphorylation and degradation of HMG CoA reductase.

R. Parker, S. Miller, D. Gibson, 1989, Advances in enzyme regulation.

7 Hydroxymethylglutaryl-Coenzyme A Reductase

R. Parker, D. Gibson, 1987 .

Phosphorylation state of HMG CoA reductase affects its catalytic activity and degradation.

R. Parker, S. Miller, D. Gibson, 1986, Advances in enzyme regulation.

Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression

R. Parker, P. Shipkova, C. Ryan, 2013, Journal of Lipid Research.

Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols.

R. Parker, A. Qureshi, K. Volk, 1994, Journal of medicinal chemistry.

Inhibitors of Cholesterol Biosynthesis. Part 2. Hypocholesterolemic and Antioxidant Activities of Benzopyran and Tetrahydronaphthalene Analogues of the Tocotrienols.

R. Parker, A. Qureshi, K. Volk, 1994 .

Modulation of hydroxymethylglutaryl-CoA reductase activity, reductase kinase activity, and cholesterol synthesis in rat hepatocytes in response to insulin and glucagon.

R. Parker, T. Ingebritsen, M. Geelen, 1979, The Journal of biological chemistry.

Short-term regulation of hydroxymethylglutaryl coenzyme A reductase by reversible phosphorylation: modulation of reductase phosphatase in rat hepatocytes.

R. Parker, K. Evenson, D. Gibson, 1982, Advances in enzyme regulation.

HMG-CoA reductase inhibitors 4. Tetrazole series: conformational constraints and structural requirements at the hydrophobic domain.

R. Parker, J. BrownPeter, John J. Wright, 1992 .

Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors.

R. Parker, L. Hamann, M. Kirby, 2007, Bioorganic & medicinal chemistry letters.

Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors.

R. Parker, L. Hamann, M. Kirby, 2013, Bioorganic & medicinal chemistry letters.

Activation of the branched-chain alpha-ketoacid dehydrogenase complex by a broad specificity protein phosphatase.

R. Parker, R. Harris, R. Paxton, 1982, Biochemical and biophysical research communications.

Regulation of liver hydroxymethylglutaryl-CoA reductase by a bicyclic phosphorylation system.

R. Parker, T. Ingebritsen, D. Gibson, 1981, The Journal of biological chemistry.

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

R. Parker, L. Hamann, M. Kirby, 2005, Journal of medicinal chemistry.

RMI 15,731 (1-[5-tetradecyloxy-2-furanyl]-ethanone), a new antirhinovirus compound

R. Parker, G. Mayer, A. Hagan, 1979, Antimicrobial Agents and Chemotherapy.

The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical Implications

R. Parker, K. Yarasheski, O. Flint, 2009, Toxicologic pathology.

Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

R. Parker, D. Gordon, B. Pearce, 1993, The Journal of biological chemistry.

Hypocholesterolemic activity of synthetic and natural tocotrienols.

R. Parker, A. Qureshi, B. Pearce, 1992, Journal of medicinal chemistry.

Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically

R. Parker, O. Flint, M. Noor, 2006, AIDS.

Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2

R. Parker, G. Atsumi, M. Linton, 2007, Nature.

Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes.

Keita Kono, R. Parker, G. Atsumi, 2005, Cell metabolism.

Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice.

R. Parker, K. Uysal, S. Wiesbrock, 1999, Diabetes.

Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).

David S. Taylor, R. Parker, R. Stoffel, 2007, Bioorganic & medicinal chemistry letters.

Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation

A. Prat, N. Seidah, R. Parker, 2009, The Journal of Biological Chemistry.

Phosphorylation of microsomal HMG CoA reductase increases susceptibility to proteolytic degradation in vitro.

R. Parker, S. Miller, D. Gibson, 1984, Biochemical and biophysical research communications.

A potent, tissue-selective, synthetic inhibitor of HMG-CoA reductase.

R. Parker, S. Sit, J. J. Wright, 1989, Journal of medicinal chemistry.

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation

A. Prat, N. Seidah, R. Parker, 2012, PloS one.

Effects of the Prosegment and pH on the Activity of PCSK9

N. Seidah, R. Parker, S. Benjannet, 2010, The Journal of Biological Chemistry.

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

R. Parker, D. Haas, M. Noor, 2004, AIDS.

Phosphorylation of native 97-kDa 3-hydroxy-3-methylglutaryl-coenzyme A reductase from rat liver. Impact on activity and degradation of the enzyme.

R. Parker, S. Miller, D. Gibson, 1989, The Journal of biological chemistry.

Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering

Doree Sitkoff, Daniel Meyers, R. Parker, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Synthesis, biological profile, and quantitative structure-activity relationship of a series of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

R. Parker, W. Han, W. Harte, 1990, Journal of medicinal chemistry.

Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors.

R. Parker, L. Hamann, D. Augeri, 2004, Journal of medicinal chemistry.

Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.

R. Parker, R. Grosso, S. Sit, 1990, Journal of lipid research.

Turnover of HMG CoA Reductase is Influenced by Phosphorylation

R. Parker, D. Gibson, Steven J. Miller, 1987 .

Running title : PCSK 9-enhanced LDLR degradation 1 EFFECTS OF THE PROSEGMENT AND PH ON THE ACTIVITY OF PCSK 9 : EVIDENCE FOR ADDITIONAL PROCESSING EVENTS

N. Seidah, R. Parker, S. Benjannet, 2010 .

Phosphorylation of HMG CoA reductase increases its susceptibility to proteolysis in hepatocytes and in vitro

R. Parker, D. Gibson, Steven J. Miller, 1985 .